We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Ultragenyx Pharmaceutical Inc (RARE) USD0.001

Sell:$39.90 Buy:$39.93 Change: $1.34 (3.26%)
Market closed |  Prices as at close on 23 May 2024 | Switch to live prices |
Change: $1.34 (3.26%)
Market closed |  Prices as at close on 23 May 2024 | Switch to live prices |
Change: $1.34 (3.26%)
Market closed |  Prices as at close on 23 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.

Contact details

60 Leveroni Ct
United States
+1 (415) 4838800

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$3.37 billion
Shares in issue:
83.13 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Emil Kakkis
    President, Chief Executive Officer, Director
  • Howard Horn
    Chief Financial Officer, Executive Vice President, Corporate Strategy
  • Dennis Huang
    Executive Vice President, Chief Technical Operations Officer and Gene Therapy Operations
  • Karah Parschauer
    Executive Vice President, Chief Legal Officer, General Counsel
  • Eric Crombez
    Executive Vice President, Chief Medical Officer
  • Erik Harris
    Executive Vice President, Chief Commercial Officer
  • Thomas Kassberg
    Chief Business Officer, Executive Vice President
  • John Pinion
    Chief Quality Officer, Executive Vice President - Translational Sciences

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.